CASI appoints Spectrum CEO to board
This article was originally published in Scrip
Executive Summary
CASI Pharmaceuticals, a biopharmaceutical company dedicated to the acquisition, development and commercialization of innovative therapeutics addressing cancer and other unmet medical needs with a primary focus on China, has elected Dr Rajesh C Shrotriya to its board of directors. Dr Shrotriya is currently chair and CEO of Spectrum Pharmaceuticals. The appointment was made in connection with the recently announced acquisition of greater China rights to three of Spectrum's oncology drugs.